Inactive

This is a combined synopsis/solicitation for commercial supplies/services prepared in accordance with the format in FAR Subpart 12.6 . This announcement constitutes the only solicitation; proposals ar... This is a combined synopsis/solicitation for commercial supplies/services prepared in accordance with the format in FAR Subpart 12.6 . This announcement constitutes the only solicitation; proposals are being requested and no additional written solicitation will be issued. The solicitation number is 75D301-20-R-68127. This solicitation is to obtain laboratory testing services for CDC Multistate Assessment of SARS-CoV-2 Seroprevalence (MASS) Study with an estimated start date of October 12, 2020. This procurement is being conducted full and open with no set aside. Proposals are due by September 9, 2020, at 5PM EST. Offers shall be submitted via e-mail. (Note: posting modification on August 20, 2020, amended the proposal due date to September 9, 2020.) UPDATED: Only one question was submitted in response to this posting. Please see below for question and response. Question: Under Deliverables, Critical Elements, it states that “Testing will include CLIA-approved and/or EUA-approved ELISA, COVID-19 IgG and IgM serological assays" does that mean that CLIA-approved and/or EUA-approved ELISAs only will be accepted? CDC Response: For Task 1, CDC does not intend to consider non-CLIA/EUA tests. For Tasks 2 and 3, CDC will assess non-CLIA/EUA tests based on performance and alternative availability. However, CLIA/EUA tests will receive preference in our evaluation.